<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00298155</url>
  </required_header>
  <id_info>
    <org_study_id>28741</org_study_id>
    <secondary_id>FHCRC-05026</secondary_id>
    <secondary_id>05-8538-V 01</secondary_id>
    <secondary_id>28741-A</secondary_id>
    <secondary_id>01253</secondary_id>
    <nct_id>NCT00298155</nct_id>
  </id_info>
  <brief_title>Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer</brief_title>
  <acronym>TAPS</acronym>
  <official_title>Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prostate cancer (CaP) is the most commonly diagnosed cancer among males in the U.S. and the
      second leading cause of cancer-related mortality. More than 230,000 men will be diagnosed
      with prostate cancer in the USA this year and more than 30,000 will die of this disease.

      Androgen deprivation, the elimination of testosterone and its active metabolites, remains the
      single most effective intervention available for the treatment of advanced prostate
      carcinoma. This is usually achieved by surgical removal of the testes (orchiectomy), by
      suppressing production of testosterone (LHRH agonists) and/or by blocking the androgens at
      receptor sites (antiandrogens). Unfortunately, androgen suppression does not cure the
      disease. Most patients progress within 0-5 years, and all patients ultimately progress if the
      cancer is not eliminated during initial therapy (usually prostatectomy or radiation).

      Hormone suppression treatment eliminates the detectable levels of testosterone in the blood.
      However, the testosterone levels in tissue remain high enough to stimulate androgen
      receptors. Overexpression of androgen receptors is present in all cell lines which
      demonstrate &quot;androgen independence,&quot; i.e., are resistant to androgen-suppressive therapy.

      Approximately 95% of testosterone is supplied by the testes, with the remaining 5% supplied
      by the adrenal glands. The presumption that standard androgen deprivation achieves the
      optimal level of androgen suppression for patients is based on the levels of androgen which
      result from orchiectomy. However, because adrenal androgen levels are unaffected by standard
      modes of androgen deprivation, 5% of the body's testosterone remains despite hormone therapy.

      The hypothesis of this study is that more effective suppression of the androgen axis through
      elimination of adrenal androgens and more effective suppression of testosterone metabolites
      will lower intraprostatic androgen levels, minimizing activation of the androgen receptor and
      augmenting natural cell death (apoptosis). The investigators propose to test this hypothesis
      by administering neoadjuvant (pre-surgery) androgen deprivation therapy of different types
      before prostatectomy for patients with clinically localized prostate cancer. The
      investigators will assay serum and intraprostatic androgen levels, while assessing relative
      levels of apoptosis of normal and malignant tissue.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Androgen deprivation has been the principal means of controlling advanced prostate cancer,
      but does not cure the disease and all patients ultimately progress if the tumor is not
      eliminated with definitive local therapy. It has been demonstrated that despite androgen
      deprivation with LHRH agonists or orchiectomy, prostate tissue and prostate cancer maintain
      levels of androgens which are more than adequate to stimulate the androgen receptor. These
      levels of androgen may continue to stimulate the receptor and allow both survival of tumor
      cells and induction of resistance by overexpression of the receptor. The presumption that
      standard androgen deprivation achieves the optimal level of androgen suppression for patients
      is based on the levels of androgen achieved with castration, which achieves relatively short
      term control of cancer in the majority of patients. The hypothesis of this study is that more
      effective suppression of the androgen axis through elimination of adrenal androgens and more
      effective suppression of conversion to dihydrotestosterone will lower intraprostatic androgen
      levels, minimizing activation of the androgen receptor and augmenting apoptosis. We propose
      to test this hypothesis in a prospective, randomized trial, administering neoadjuvant
      androgen deprivation therapy of different types prior to radical prostatectomy for patients
      with clinically localized prostate cancer for 3 months.

      Plan of therapy

      Patients with clinically localized (cT1-T2) prostate cancer, at intermediate-high risk for
      relapse who are candidates for radical prostatectomy will be treated with one of three
      regimens:

        -  Goserelin with dutasteride

        -  Goserelin with bicalutamide and dutasteride

        -  Goserelin with bicalutamide and dutasteride and ketoconazole

      Patients will undergo radical prostatectomy 3 months after initiation of treatment.

      Preoperative and intraoperative biopsies of the prostate gland will be utilized for analysis
      of prostatic hormones, gene expression and apoptosis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Endpoint of the Study is to Evaluate the Effect of Different Combinations of Anti-androgen Medicines on Androgen Levels in the Prostate Tissue</measure>
    <time_frame>post-treatment</time_frame>
    <description>Tissue dihydrotesterone (DHT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Determine the Effects of Different Modes of Androgen Deprivation on Serum DHT, T, Dehydroepiandrosterone (DHEA) and Androstenedione</measure>
    <time_frame>post-treatment</time_frame>
    <description>Serum DHT</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Cancer</condition>
  <condition>Prostate Neoplasms</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Goserelin + dutasteride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bicalutamide for one week, begin goserelin plus dutasteride, continue bicalutamide for the full 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Begin bicalutamide for one week, goserelin injection; begin dutasteride, ketoconazole (and replacement hydrocortisone), continue bicalutamide for the full 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>goserelin with dutasteride</intervention_name>
    <description>Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot) and begin dutasteride 3.5 mg qd; continue bicalutamide for one more week.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>goserelin with bicalutamide and dutasteride</intervention_name>
    <description>Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot) and begin dutasteride 3.5 mg qd.</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>goserelin with bicalutamide and dutasteride and ketoconazole</intervention_name>
    <description>Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot), begin dutasteride 3.5 mg qd and ketoconazole 200 mg tid (with hydrocortisone 30 mg).</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men 18 years or older with a histologic diagnosis of clinically localized prostate
             cancer prior to radical prostatectomy as defined by:

               -  Clinical stage T1-T2b

               -  Prostate specific Antigen (PSA) less than 20

               -  Gleason score 7-10

          2. Patient's tumor must be considered surgically resectable .

          3. Eastern Cooperative Group (ECOG) performance status of 0-1.

          4. Life expectancy greater than 2 years.

          5. Able to understand and give informed consent.

          6. Laboratory values must be within specified limits.

        Exclusion Criteria:

          1. Patients with locally advanced or high risk disease not meeting the criteria defined
             above.

          2. Patients who have a total testosterone less than 280 ng/dL.

          3. Patients who are receiving any other investigational therapy.

          4. Patients with an active serious infection or other serious underlying medical
             condition.

          5. Dementia or significantly altered mental status that would prohibit the understanding
             and/or giving of informed consent.

          6. Histologic evidence of small cell carcinoma of the prostate.

          7. Patients who are currently receiving active therapy for other neoplastic disorders.

          8. Patients who are receiving any androgens, estrogens or progestational agents.

          9. Patients who are taking drugs or herbal supplements which affect androgen metabolism
             (e.g., spironolactone, aprepitant, bexarotene, clarithromycin, itraconazole,
             ketoconazole, St. John's wort).

         10. Patients who have chronic active hepatitis.

         11. Patients taking any of the following medications who cannot discontinue these
             medications for three months during administration of ketoconazole; statin cholesterol
             medications, cyclosporine, isoniazid, rifampin, terfenadine, triazolam or astemizole.

         12. Patients who have history of cerebrovascular accident, deep venous thrombosis,
             pulmonary emboli, unstable angina or clinical congestive heart failure.

         13. Medical conditions, which, in the opinion of the investigators would jeopardize either
             the patient or the integrity of the data obtained.

         14. Patients unwilling to use contraceptives while on study.

         15. Patients with a risk of nodal involvement of greater than 10% should have received a
             bone scan and CT of the pelvis prior to screening for the study as part of standard of
             care.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R. Bruce Montgomery, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington; Seattle Cancer Care Alliance; VA Puget Sound HCS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter S. Nelson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center; Seattle Cancer Care Alliance</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veterans' Administration Puget Sound Health Care System (VAPSHCS)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108-1532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195-6158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Mostaghel EA, Nelson PS, Lange P, Lin DW, Taplin ME, Balk S, Ellis W, Kantoff P, Marck B, Tamae D, Matsumoto AM, True LD, Vessella R, Penning T, Hunter Merrill R, Gulati R, Montgomery B. Targeted androgen pathway suppression in localized prostate cancer: a pilot study. J Clin Oncol. 2014 Jan 20;32(3):229-37. doi: 10.1200/JCO.2012.48.6431. Epub 2013 Dec 9.</citation>
    <PMID>24323034</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2006</study_first_submitted>
  <study_first_submitted_qc>February 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2006</study_first_posted>
  <results_first_submitted>March 26, 2017</results_first_submitted>
  <results_first_submitted_qc>March 26, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 8, 2017</results_first_posted>
  <last_update_submitted>March 26, 2017</last_update_submitted>
  <last_update_submitted_qc>March 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Bruce Montgomery</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Androgens</mesh_term>
    <mesh_term>Ketoconazole</mesh_term>
    <mesh_term>Dutasteride</mesh_term>
    <mesh_term>Bicalutamide</mesh_term>
    <mesh_term>Goserelin</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>Paper with attached protocol and outcomes</doc_type>
      <doc_url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3887479/</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1</title>
          <description>Goserelin + dutasteride
goserelin with dutasteride: Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot) and begin dutasteride 3.5 mg qd; continue bicalutamide for one more week.</description>
        </group>
        <group group_id="P2">
          <title>Group 2</title>
          <description>Bicalutamide for one week, begin goserelin plus dutasteride, continue bicalutamide for the full 12 weeks
goserelin with bicalutamide and dutasteride: Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot) and begin dutasteride 3.5 mg qd.</description>
        </group>
        <group group_id="P3">
          <title>Group 3</title>
          <description>Begin bicalutamide for one week, goserelin injection; begin dutasteride, ketoconazole (and replacement hydrocortisone), continue bicalutamide for the full 12 weeks
goserelin with bicalutamide and dutasteride and ketoconazole: Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot), begin dutasteride 3.5 mg qd and ketoconazole 200 mg tid (with hydrocortisone 30 mg).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>Goserelin + dutasteride
goserelin with dutasteride: Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot) and begin dutasteride 3.5 mg qd; continue bicalutamide for one more week.</description>
        </group>
        <group group_id="B2">
          <title>Group 2</title>
          <description>Bicalutamide for one week, begin goserelin plus dutasteride, continue bicalutamide for the full 12 weeks
goserelin with bicalutamide and dutasteride: Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot) and begin dutasteride 3.5 mg qd.</description>
        </group>
        <group group_id="B3">
          <title>Group 3</title>
          <description>Begin bicalutamide for one week, goserelin injection; begin dutasteride, ketoconazole (and replacement hydrocortisone), continue bicalutamide for the full 12 weeks
goserelin with bicalutamide and dutasteride and ketoconazole: Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot), begin dutasteride 3.5 mg qd and ketoconazole 200 mg tid (with hydrocortisone 30 mg).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="13"/>
            <count group_id="B4" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="41" upper_limit="82"/>
                    <measurement group_id="B2" value="66" lower_limit="41" upper_limit="82"/>
                    <measurement group_id="B3" value="60" lower_limit="41" upper_limit="82"/>
                    <measurement group_id="B4" value="64" lower_limit="41" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Endpoint of the Study is to Evaluate the Effect of Different Combinations of Anti-androgen Medicines on Androgen Levels in the Prostate Tissue</title>
        <description>Tissue dihydrotesterone (DHT)</description>
        <time_frame>post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Goserelin + dutasteride
goserelin with dutasteride: Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot) and begin dutasteride 3.5 mg qd; continue bicalutamide for one more week.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Bicalutamide for one week, begin goserelin plus dutasteride, continue bicalutamide for the full 12 weeks
goserelin with bicalutamide and dutasteride: Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot) and begin dutasteride 3.5 mg qd.</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Begin bicalutamide for one week, goserelin injection; begin dutasteride, ketoconazole (and replacement hydrocortisone), continue bicalutamide for the full 12 weeks
goserelin with bicalutamide and dutasteride and ketoconazole: Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot), begin dutasteride 3.5 mg qd and ketoconazole 200 mg tid (with hydrocortisone 30 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Endpoint of the Study is to Evaluate the Effect of Different Combinations of Anti-androgen Medicines on Androgen Levels in the Prostate Tissue</title>
          <description>Tissue dihydrotesterone (DHT)</description>
          <units>ng/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.01"/>
                    <measurement group_id="O2" value="0.06" spread="0.06"/>
                    <measurement group_id="O3" value="0.03" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Determine the Effects of Different Modes of Androgen Deprivation on Serum DHT, T, Dehydroepiandrosterone (DHEA) and Androstenedione</title>
        <description>Serum DHT</description>
        <time_frame>post-treatment</time_frame>
        <population>Full details of all androgens in the paper J Clinical Oncology VOLUME 32 NUMBER 3 JANUARY 20 2014</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Goserelin + dutasteride
goserelin with dutasteride: Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot) and begin dutasteride 3.5 mg qd; continue bicalutamide for one more week.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Bicalutamide for one week, begin goserelin plus dutasteride, continue bicalutamide for the full 12 weeks
goserelin with bicalutamide and dutasteride: Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot) and begin dutasteride 3.5 mg qd.</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Begin bicalutamide for one week, goserelin injection; begin dutasteride, ketoconazole (and replacement hydrocortisone), continue bicalutamide for the full 12 weeks
goserelin with bicalutamide and dutasteride and ketoconazole: Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot), begin dutasteride 3.5 mg qd and ketoconazole 200 mg tid (with hydrocortisone 30 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>To Determine the Effects of Different Modes of Androgen Deprivation on Serum DHT, T, Dehydroepiandrosterone (DHEA) and Androstenedione</title>
          <description>Serum DHT</description>
          <population>Full details of all androgens in the paper J Clinical Oncology VOLUME 32 NUMBER 3 JANUARY 20 2014</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="3.4"/>
                    <measurement group_id="O2" value="3.6" spread="2.0"/>
                    <measurement group_id="O3" value="5.7" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>Goserelin + dutasteride
goserelin with dutasteride: Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot) and begin dutasteride 3.5 mg qd; continue bicalutamide for one more week.</description>
        </group>
        <group group_id="E2">
          <title>Group 2</title>
          <description>Bicalutamide for one week, begin goserelin plus dutasteride, continue bicalutamide for the full 12 weeks
goserelin with bicalutamide and dutasteride: Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot) and begin dutasteride 3.5 mg qd.</description>
        </group>
        <group group_id="E3">
          <title>Group 3</title>
          <description>Begin bicalutamide for one week, goserelin injection; begin dutasteride, ketoconazole (and replacement hydrocortisone), continue bicalutamide for the full 12 weeks
goserelin with bicalutamide and dutasteride and ketoconazole: Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot), begin dutasteride 3.5 mg qd and ketoconazole 200 mg tid (with hydrocortisone 30 mg).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hot flushes</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Bruce Montgomery</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-598-0860</phone>
      <email>rbmontgo@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

